Yahoo Finance

Needham raised the firm’s price target on SI-Bone (SIBN) to $20 from $19 and keeps a Buy rating on the shares as part of a broader research note on MedTech/Diagnostics sector. Following the recent pre-announcements and management commentary, the firm is updating its forecasts on select names while also rolling forward its valuation framework to 2026 estimates, the analyst tells investors in a research note.

Invest with Confidence:

• Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.

• Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on SIBN:

• SI-Bone sees Q4 revenue $48.8M-$49M, consensus $46.89M

• SI-Bone assumed with an Overweight at Morgan Stanley